UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Zhejiang University-backed optical chip maker XY Technology will put the series B cash to strengthening its capacity and product.

Bell Food Group and M Ventures have contributed to an initial $55m series B tranche for the cultured meat developer spun out of Maastricht University.

University of London-linked Monte Rosa Therapeutics is working on biotechnology to degrade disease-driving proteins that have hitherto been considered undruggable.

Creative Biosciences has collected $88m in fresh funding, five years after being founded by a Sun Yat-Sen University professor.

A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.

Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.

CMU's warehouse vehicle manufacturer Seegrid has more than doubled its latest round to $52m, building on an initial $25m from G2VP six months ago.